The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000051.3(ATM):c.1073A>G (p.Asn358Ser)

CA286708

127329 (ClinVar)

Gene: ATM
Condition: hereditary breast cancer
Inheritance Mode: Autosomal dominant inheritance
UUID: e78376c1-7f08-4335-87ea-e4c47d2801ff
Approved on: 2022-03-09
Published on: 2022-07-11

HGVS expressions

NM_000051.3:c.1073A>G
NM_000051.3(ATM):c.1073A>G (p.Asn358Ser)
NC_000011.10:g.108248940A>G
CM000673.2:g.108248940A>G
NC_000011.9:g.108119667A>G
CM000673.1:g.108119667A>G
NC_000011.8:g.107624877A>G
NG_009830.1:g.31109A>G
ENST00000278616.9:c.1073A>G
ENST00000682516.1:n.1207A>G
ENST00000682956.1:n.1207A>G
ENST00000683174.1:n.1223A>G
ENST00000683605.1:n.568A>G
ENST00000684037.1:c.*8A>G
ENST00000684061.1:n.1207A>G
ENST00000684179.1:n.1042A>G
ENST00000527805.6:c.1073A>G
ENST00000675595.1:c.908A>G
ENST00000675843.1:c.1073A>G
ENST00000278616.8:c.1073A>G
ENST00000452508.6:c.1073A>G
ENST00000527805.5:c.1073A>G
NM_001351834.1:c.1073A>G
NM_001351834.2:c.1073A>G
NM_000051.4:c.1073A>G
NM_000051.4(ATM):c.1073A>G (p.Asn358Ser)
More

Benign

Met criteria codes 3
BP2_Strong BS1 BP4
Not Met criteria codes 4
PP3 PM2 BA1 PS1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for ATM Version 1.1

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Hereditary Breast, Ovarian and Pancreatic Cancer VCEP
The ATM c.1073A>G (p.Asn358Ser) variant has a gnomAD v2.1.1 filtering allele frequency of 0.1523% (African/African-American; exomes) which exceeds the ATM BS1 threshold of 0.05% (BS1). This variant has been observed in a homozygous and compound heterozygous state (presumed) in multiple individuals without biallelic disease (BP2_Strong; GTR Lab IDs: 500031, 61756). In silico protein predictors (ALIGN GVGD: Class C0; REVEL: 0.054; SIFT: tolerated; PolyPhen2: benign) predict that this alteration is not deleterious and in silico splicing predictors (SpliceAI: AL 0.13/DL 0.00/AG 0.00/DG 0.00; MaxEntScan: 0.00% (wild type = 10.82, variant = 10.82)) find that this variant is unlikely to affect splicing (BP4). In summary, this variant meets criteria to be classified as benign based on the ACMG/AMP criteria applied as specified by the HBOP Variant Curation Expert Panel.
Met criteria codes
BP2_Strong
This variant has been observed in a homozygous and compound heterozygous state (presumed) in multiple individuals without biallelic disease (BP2_Strong; GTR Lab IDs: 500031, 61756).
BS1
GnomAD v2.1.1 FAF 0.1523% (African/African-American; exomes) exceeds ATM BS1 threshold of 0.05%.
BP4
In silico protein predictors (ALIGN GVGD: Class C0; REVEL: 0.054; SIFT: tolerated; PolyPhen2: benign) predict that this alteration is not deleterious and in silico splicing predictors (SpliceAI: AL 0.13/DL 0.00/AG 0.00/DG 0.00; MaxEntScan: 0.00% (wild type = 10.82, variant = 10.82)) find that this variant is unlikely to affect splicing (BP4).
Not Met criteria codes
PP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.